Avro is a life sciences company, located in Canada and founded in 2016 by Shakir Lakhani and Keean Waterloo, Ontario, that makes skin patches capable of delivering generic drugs. The skin patches Avro makes focus on generic drug delivery, with a special focus on drug delivery for children and the elderly.
In an interview on February 18th, 2018, co-founder Sakir Lakhani stated that Avro will be working on developing its first commercially available skin patch that can safely and effectively deliver allergy medicine. The skin patch will be in the form of a sticker that is designed to be used by children.
Each sticker delivers an antihistamine as well as other allergy fighting molecules. The patches can be used by children, as well as elderly people, bariatric patients, and those who suffer from dysphagia. The patch uses a novel bioploymer as a base for a passive transdermal drug delivery system, and the effects are designed to match metabolism rates of users to allow for a safer consumption.
In December 2016, Avro won $25,000 in the Velocity Fund pitch competition.
On June 1, 2017 Avro won the Grants4Apps Toronto Competition receiving $10,000 and office space for 88 days at Bayer's Canadian headquarters.
Avro finished its seed funding round on January 4, 2018 raising $120,000 in funding from Y Combinator.
At Y Combinator's Demo Day, the Age of Overpromises Is Over
Avro Life Science | James Dyson Award
James Dyson Award staff
Life sciences startup Avro aims to deliver drugs to children and the elderly through skin patches
Two University of Waterloo startups Canadian finalists in annual James Dyson Awards